DiaMedica Therapeutics Inc. (DMAC): Cash & Equivalents
$15.65M
As of 2025-12-31
$5.13M
As of 2026-06-30
+49.0%
3-year compound annual growth
+16.1%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $15.65M | +417.3% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $3.02M | -33.4% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $4.54M | -3.9% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $4.73M | +0.4% | 2024-03-19, Balance as of period end |
| 2021-12-31 | $4.71M | -36.5% | 2023-03-28, Balance as of period end |
| 2020-12-31 | $7.41M | +90.8% | 2022-03-14, Balance as of period end |
| 2019-12-31 | $3.88M | -76.9% | 2021-03-10, Balance as of period end |
| 2018-12-31 | $16.82M | n/a | 2020-03-23, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | $15.65M | +417.3% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $48.30M | -38.1% |
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | $19.94M | -6.6% |
| Lifevantage Corp (LFVN) | 2025-06-30 | $20.20M | +19.6% |
| OnKure Therapeutics, Inc. (OKUR) | 2025-12-31 | $59.05M | -46.7% |
| Rallybio Corp (RLYB) | 2025-12-31 | $31.37M | +125.7% |
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $55.16M | +696.8% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $90.0K | -86.7% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $57.98M | -30.6% |
Compare DMAC, QTTB, ANTX, LFVN side by side · Screen every company in Pharmaceutical Preparations ↗